Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
Both plasma p-tau217 assays were strongly associated with amyloid and tau PET.
-
Recent advances in blood-based biomarkers of Alzheimer's Disease (AD) show great promise for clinical applications, offering a less invasive alternative to current cerebrospinal fluid (CSF) measures.
-
59/100
53% of participants were CMV seropositive.
-
The GWAS identified a significant single nucleotide polymorphism (SNP), rs17149074, within the C9orf171 (CFAP77) gene region that showed significant association with changes in CSF t-tau over time.
-
Plasma p-tau is a stronger indicator of a temporally linked response to elevated brain Aβ than of tau pathology.
-
Plasma amyloid-β (Aβ)42, phosphorylated tau (p-tau)181, and neurofilament light chain (NfL) are promising biomarkers of Alzheimer's disease (AD).
-
We found non-significant differences in age (F(2, 141) = 1.304; P = 0.275) and years of education (F(2, 141) = 0.013; P = 0.987).
-
Longitudinal multimodal biomarker studies reveal that the continuum of Alzheimer's disease (AD) includes a long latent phase, referred to as preclinical AD, which precedes the onset of symptoms by decades.
-
Vascular risk significantly predicted cerebral amyloid burden in Alzheimer's Disease Neuroimaging Initiative but not in the UCD-ADRC cohort.
-
59/100
Early identification of cognitive impairment in Parkinson’s disease (PD) has important clinical and research implications.
-
We constructed a panel combining plasma NfL and GFAP with known AD risk factors (Combination panel: age+sex+APOE4+GFAP+NfL).
-
Comparable diagnostic performances and strong correlations between serum versus plasma pairs suggest that p-tau analyses can be expanded to research cohorts and hospital systems that prefer serum to other blood matrices.
-
Blood-brain-barrier (BBB) dysfunction is a hallmark of aging and aging-related disorders, including cerebral small vessel disease and Alzheimer's disease.
-
We sought to identify cognitive measures associated with the earliest detectable signs of emerging Aβ and tau pathology.
-
Our findings demonstrated a significant association between plasma NFL levels and disrupted WM microstructure across the brain.
-
CSF total aSyn was decreased. NfL, pNfH, UCHL-1, GFAP, S100B, and sTREM-2 were increased in patients with neurodegenerative disease versus HC (P < 0.05).
-
P-tau and NfL behave differently within the same individuals over time and may therefore offer complementary diagnostic information.
-
59/100
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are two related currently incurable neurodegenerative diseases.
-
Plasma P-tau181/Aβ42 ratio may be a noninvasive means of identifying AD with elevated brain amyloid in populations with concomitant CeVD.
-
ChT was increased in people with DS (pwDS) compared to Ctrl.
-
59/100
A total of 124 eyes of 69 participants with PD (39 men [56.5%]; mean [SD] age, 71.7 [7.0] years) and 248 eyes of 137 control participants (77 men [56.2%]; mean [SD] age, 70.9 [6.7] years) were analyzed.
-
N-p-tau217 and N-p-tau181 could improve diagnostic accuracy in prodromal-AD and clinical trial recruitment as both identify Aβ pathophysiology and differentiate early MCI-AD better than Mid-p-tau181.
-
Positron emission tomography (PET)-based staging of regional amyloid deposition has recently emerged as a promising tool for sensitive detection and stratification of pathology progression in Alzheimer's Disease (AD).
-
Virtually identical t-tau/Aβ42 cut-points (∼0.54) performed best in both test cohorts and with similar accuracy (areas under ROC curve [AUCs] [A/B: 0.95; C: 0.94]).
-
Plasma lipocalin-2 levels were higher in preclinical AD compared with control subjects and associated with cerebrospinal fluid amyloid-beta42 levels but not cerebrospinal fluid tau or phosphorylated-tau181 levels.
From across this topic
10 of the 1,573 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Stability of blood-based biomarkers of Alzheimer's disease over multiple freeze-thaw cycles
- Impact of harmonization of collection tubes on Alzheimer's disease diagnosis
- Plasma Total Tau and Neurobehavioral Symptoms of Cognitive Decline in Cognitively Normal Older Adults
- Olfactory Bulb Amyloid-β Correlates With Brain Thal Amyloid Phase and Severity of Cognitive Impairment
- Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease
- Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCe project
- Early-phase [18F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury
- Tau-positron emission tomography correlates with neuropathology findings
- Investigation of coenzyme Q10 status, serum amyloid-β, and tau protein in patients with dementia
- Diagnostic Concordance Between Plasma p-Tau217 and Amyloid-β Biomarkers in Symptomatic Alzheimer's Disease: Evidence From a Chinese Cohort